Laurie Burlingame is a partner in the firm’s nationally recognized Life Sciences group. She represents private and public companies across the spectrum of the life sciences industry, including pharmaceuticals, medical devices, diagnostics and biological materials. Ms. Burlingame also represents leading venture capital firms focused on the life sciences industry in connection with their portfolio company investments.

Ms. Burlingame often serves as outside general counsel to her clients, closely advising management teams and boards of directors on a wide variety of matters throughout the company’s life cycle, including formation and founder issues, venture capital financings, public offerings, mergers and acquisitions, licensing transactions, strategic collaborations, commercial transactions, corporate governance and other general corporate matters.

Experience

ERFAHRUNG

EXPÉRIENCE

工作经历

A selection of Ms. Burlingame’s recent client representations includes:

Representative Matters

REFERENZMANDATE

代表事项

Public Offerings
  • SpringWorks Therapeutics, Inc. in its 2019 initial public offering
  • Axcella Health Inc. in its 2019 initial public offering in its $60.1 million follow-on offering and subsequent $35 million “at the market” offering
  • Kaleido Biosciences Inc. in its 2019 initial public offering in its $35.6 million follow-on offering
  • Akero Therapeutics Inc. in its 2019 initial public offering
  • Scholar Rock Holding Corporation in its 2018 initial public offering and follow-on public offering
  • Neon Therapeutics, Inc. in its 2018 initial public offering
  • Voyager Therapeutics, Inc. in its 2016 initial public offering
  • Celyad S.A. in its 2015 U.S. initial public offering
  • Blueprint Medicines Corporation in its 2015 initial public offering
  • Sage Therapeutics, Inc. in its 2014initial public offering and follow-on public offerings
  • Zafgen, Inc. in its 2014 initial public offering and several of its follow-on public offerings
Corporate Formations and Venture Capital Financings
  • Cerevance, LLC in its $65 million Series B Preferred Unit financing
  • Xilio Therapeutics, LLC in its $100 million Series B Preferred Unit financing
  • Admirx Inc. in its $43 million Series A Preferred Stock financing
  • SpringWorks Therapeutics, Inc. in its $125 million Series B Preferred Stock financing
  • Gemini Therapeutics, Inc. in its Series B Preferred Stock financing and Series A Preferred Stock financing
  • Akero Therapeutics, Inc. in its Series B Preferred Stock financing and Series A Preferred Stock financing
  • Axcella Health in its Series E Preferred Stock financing
  • Kaleido Biosciences Inc. in its $101 Series B Preferred Stock financing
  • Cadent Therapeutics, Inc. in its $40 million Series B Preferred Stock financing
  • Neon Therapeutics, Inc. in its formation, $55 million Series A Preferred Stock financing and $70 million Series B Preferred Stock financing
  • Voyager Therapeutics, Inc. in its formation, $47 million Series A Preferred Stock financing and $60 million Series B Preferred Stock financing
  • Mevion Medical Systems, Inc. in connection with its up to $200 million Series F Preferred Stock financing
  • SetPoint Medical Corporation in connection with its $15 million Series C-1 Preferred Stock financing,$27 million Series C Preferred Stock financing and $35 million Series C-2 Preferred Stock financing
  • Scholar Rock Holding Corporation in its Series C Preferred Stock financing, Series B Preferred Unit financing and its Series A Preferred Unit financing
  • RaNA Therapeutics, LLC in its Series B Preferred Unit financing
  • iWalk, Inc. in its Series E Preferred Stock financing
  • NinePoint Medical, Inc. in its $34 million Series B Preferred Stock financing and Series C Preferred Stock financing
  • Cerevance, LLC in its Series A Preferred Unit financing
  • Accelerator IV-New York Corporation and Accelerator IV-Seattle Corporation in their formation and funding
  • AgTech Accelerator Corporation in its formation and initial funding
Mergers and Acquisitions and Strategic Collaborations
  • Flexion Therapeutics in its licensing agreement with HK Tainuo for the development and commercialization of Flexion’s product ZILRETTA® in Greater China
  • Mevion Medical Systems, Inc. in connection with its merger transaction
  • Acetylon Pharmaceuticals, Inc. in its up to $1.7 billion collaboration and buyout option transaction with Celgene Corporation, and subsequent Share Purchase Transaction with Celgene Corporation
  • Abide Therapeutics, Inc. in its collaboration and buyout option transaction with Celgene Corporation
  • ZOLL Medical Corporation in its acquisition of Advanced Circulatory Systems, Inc.
  • ZOLL Medical Corporation in its acquisition of the assets of Impact Instrumentation, Inc.
  • Nimbus Therapeutics, Inc. in connection with its innovative collaborations with Monsanto and Shire Plc
  • BionX Medical Technologies, Inc. in connection with its merger with Ottobock
Professional Experience

Ms. Burlingame is a member of Women Entrepreneurs in Science and Technology (WEST) and through the firm is a member of the Massachusetts Biotechnology Council (MBC) and MassMEDIC. She is also a member of the American and Boston Bar Associations.

Ms. Burlingame is a key contributor to Goodwin’s Founders Workbench, an online resource for start-ups, emerging companies and the entrepreneurial community. Ms. Burlingame has served as a workshop speaker and advisor to the Boston Pipeline Angels for the past several years and has provided advice to start-up companies and entrepreneurs through participation in events and office hours held by Harvard University and M.I.T.

Ms. Burlingame is a member of the Board of Directors of Sitters Without Borders, a member of the Board of Directors of Tailored for Success and a member of the Board of Directors of Mass AWIS.

Recognition

Ms. Burlingame has been the recipient of a writing award from the Boston Patent Law Association.

In The News

MELDUNGEN

ACTUALITÉS

相关新闻

Credentials

WERDEGANG

RÉFÉRENCES

专业资格

Education

J.D., 2006
Harvard Law School
M.B.A., 2003
Clark University
(concentration in accounting and finance)
A.M., Graduate School of Arts and Sciences, 2002
Harvard University
(concentration in molecular neuroscience)
B.A., 1999
Wellesley College

(summa cum laude, major in biology and psychology)

Admissions

Bar

Massachusetts
U.S. Patent and Trademark Office (USPTO)
Profile Image
Get In Touch
Kontakt
NOUS CONTACTER
联系我们
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

客户信赖我们世界一流的咨询服务,希望获得针对复杂事务性工作与高风险诉讼的建议。我们通过协作式、跨领域的工作方法来解决客户最棘手的问题,涵盖金融、生命科学、私募股权、不动产和技术等多个行业。如需更多信息,请与我们联系。

Search Other Lawyers
ANWALTSSUCHE
Recherche par Pratique
搜寻其他律师